Another one.. sigh No, IMU is being smart and not locking the two drugs together. They are both investigational drugs at this moment. That is what clinical trials are about. Best case scenario they both are game changers and yes they will use them together. Otherwise IMU is cleverly leaving their options open to use onCARlytics with another CD19 CART therapy if onCARlytics is the star of the show. And yes, it could potentially service 90% of the cancer market. No big loss here if that is the scenario. "limited utility"? well that is your opinion, much like a55holes, everyone has got one. The rest of us are waiting patiently on the data.
IMU Price at posting:
3.6¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)